These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17768093)

  • 1. Role of the nurse in preserving patients' independence.
    Maxwell C
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S38-41. PubMed ID: 17768093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
    Fitch MI; Maxwell C
    Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.
    Fitch MI
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S27. PubMed ID: 17804295
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of oncology nurses in treatment outcomes. What can we do for the patients' compliance treated with intravenous zoledronic acid?].
    Zatkóné Puskás G
    Magy Onkol; 2009 Jun; 53(2):145-8. PubMed ID: 19581180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of bone disease.
    Kinnane N
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S28-31. PubMed ID: 17768092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bisphosphonate treatment in clinical practice.
    Aapro MS
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Rosen LS
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of bisphosphonates in cancer patients.
    Wu S; Dahut WL; Gulley JL
    Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
    Saad F; Lipton A
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
    Clemons M; Dranitsaris G; Cole D; Gainford MC
    Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
    Hirsh V
    Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.